Database

1 Introduction

• Human genetics focuses on understanding Homo sapiens and the variations within our species.
• Genetic variations can be positive, negative, or neutral, impacting our ability to survive, adapt, and develop diseases.
• Studying genetic variation helps us understand human diseases, molecular genetics, biology, and the biomedical field.
• The vast majority of genetic variations occur due to errors during DNA replication.
• SNPs (Single Nucleotide Polymorphisms) are the most common type of variation, with approximately 4e5 million SNPs in a person’s genome.
• Most SNPs don’t impact development or health, but some are crucial for research, predicting drug responses, environmental vulnerabilities, and disease susceptibility.
• Despite 99.9% genomic similarity, humans have significant phenotypic differences due to the remaining 0.1% variation.
• Understanding genotype-phenotype associations is vital for personalized medicine and therapies tailored to individual genetic makeup.
• Bioinformatics and computational biology have advanced pharmacogenomics and personalized medicine, utilizing databases like PharmGKB, DrugBank, and OMIM.

2 Types of variations

• Single Nucleotide Variations: These include single nucleotide polymorphisms (SNPs) and insertions/deletions (indels). These are changes at a single nucleotide position within a DNA sequence.
• Copy Number Variations (CNVs): These are additions or deletions of DNA segments, leading to variations in the number of copies of a particular gene or sequence. CNVs can range in size from a single nucleotide to a megabase.
• Tandem Repeats: These are short sequences of DNA that repeat themselves consecutively. The number of repeats can vary between individuals, contributing to genetic diversity.
• Copy Neutral Variations: These include translocations and inversions, where segments of chromosomes are rearranged without changing the overall copy number of DNA.

The text also emphasizes that:

• CNVs are a natural part of evolution and most are harmless. However, large CNVs containing important genes can be detrimental.
• SNPs are abundant and can be used to identify genetic variations. They are detected using oligonucleotide hybridization analysis.
• The exact cause of insertions or deletions in tandem repeats is unknown.

3 Effects of genetic variation

• Genetic variation’s primary effect is to enhance a population’s adaptability to environmental challenges.
• Variations lead to evolution, a gradual change in a population over time that improves its capabilities.
• Hereditary variations, passed down from parents to offspring through egg or sperm cells, are the variations that contribute to evolution.
• Gene variants, permanent changes in DNA sequences, can cause disorders but are not always detrimental.
• Gene variations can affect protein function, potentially leading to genetic conditions or diseases.
• Genetic diseases are caused by changes in gene function, not by the genes themselves.
• Examples like cystic fibrosis demonstrate that variations in genes are common, and only certain variations cause disease.

4 Biological database

• The Rise of Biological Databases: Modern biology heavily relies on technology, generating vast amounts of data. Databases are crucial for organizing and analyzing this information.
• Applications of Biological Databases: Databases are used to understand various biological phenomena, ranging from molecular structures to organismal metabolism and evolution.
• Benefits of Biological Databases: These databases aid in disease prevention, drug development, prediction of hereditary diseases, and uncovering evolutionary relationships between species.
• Genetic Variant Databases: These databases collect and document information about genetic variations and their potential links to diseases or conditions.
• Impact on Diagnosis and Treatment: Understanding the connection between genotypes and diseases aids in the diagnosis and treatment of genetic disorders.

4.1 Database of human genetic variation

• Human Genome Variation Database (HGV): A publicly accessible database containing genetic variations documented in research papers. It provides information like mutation type, zygosity, genotype and allele frequencies, and eQTL significances.
• ClinVar: A database that links human variants to phenotypes and includes supporting documentation. It aims to facilitate understanding the connection between genotypes and clinical phenotypes.
• dbSNP: A public resource for documenting genetic variation, including SNPs, indels, STRs, and heterozygous sequences.
• 1000 Genomes Project: An international project sequencing approximately 2500 genomes from diverse populations to create a comprehensive atlas of human genetic diversity. It aims to improve genome-wide association studies by providing a broader range of genetic variation data.

4.2 Predicting the clinical significance of human genetic variation

• Molecular Genetic Testing: This testing involves analyzing a patient’s DNA for genetic diseases. It has become more accessible and efficient due to advancements in sequencing technology and computational analysis.
• Interpreting DNA Variants: Determining the clinical significance of DNA variants is a complex process. It involves a multi-step approach that includes:
  • Database Analysis: Using existing databases of genetic information.
  • Statistical Analysis: Assessing population and disease frequencies.
  • In Vitro and In Vivo Experiments: Evaluating the impact of variants.
  • Computational Prediction: Predicting the effect of each variant.
• Challenges of Variant Interpretation:
  • Variants of Uncertain Significance (VUS): Many genetic variations are unclear in their effect on disease.
  • Complexity of Genome Sequencing: The vast amount of information from genome sequencing makes interpretation challenging.
• Clinical Significance of Variants: To understand the clinical significance of a variant, consider:
  • Functionality: Does the variant affect gene function?
  • Disease Causation: Does the variant cause the disease?
  • Clinical Relevance: Is the variant associated with the patient’s present condition?
• Systematic Framework for Variant Assessment: A framework for variant assessment has been developed, categorizing variants into five sections:
  • Benign
  • Likely Benign
  • Variants of Uncertain Significance (VUS)
  • Pathogenic
  • Likely Pathogenic
• Clinical Applications: This framework helps in the clinical assessment of genetic variations, especially in diseases like cystic fibrosis.

5 Phenotype-genotype association ”## Extractive Summary of the Text:

Here is a list of key points extracted from the text:

• Genotype vs. Phenotype: Genotype refers to the genetic makeup of an individual, inherited from both parents. Phenotype refers to the observable characteristics of an individual, resulting from a complex interplay between genotype and environmental factors.
• Complexity of the Association: The relationship between genotype and phenotype is complex due to individual differences and environmental influences.
• Genotyping Techniques: Various methods like DNA microarrays, PCR, and whole-genome sequencing (WGS) are used for genotyping, providing information about an individual’s genetic makeup.
• Importance in Pharmacogenomics: Understanding genotype-phenotype association is crucial in pharmacogenomics, as it helps predict drug response and susceptibility to diseases.
• Genotype-Phenotype Association Studies: These studies are essential for understanding the evolution of traits, identifying genes responsible for behavioral characteristics, and establishing relationships between specific SNPs and diseases like diabetes, Crohn’s disease, and age-related macular degradation.
• Challenges and Future Directions: Despite advancements, understanding the complex interplay between genes and environment remains a challenge. Further research is required to refine genotype-phenotype associations and improve phenotypic prediction.

6 Pharmacogenomics

• Pharmacogenomics studies how genetic variations influence drug responses.
• Drug side effects are a significant health concern, causing millions of adverse reactions and thousands of deaths annually.
• Genetic variations can impact drug binding to receptors and metabolism, leading to differences in drug efficacy and side effects.
• Understanding an individual’s genetic makeup can help predict drug response and potentially prevent adverse reactions.

6.1 Drug receptors

• Drug receptors and genetic influence: The effectiveness of certain drugs is dependent on their attachment to specific target receptors. An individual’s genetic makeup determines the type, frequency, and specificity of these receptors, which can influence how their body responds to a particular drug.
• Genotype and drug dosage: Depending on an individual’s genotype, they may require a higher or lower dosage of a drug, or even a different drug altogether.
• Example: HER2 receptors in breast cancer: In some breast cancers, HER2 receptors are overexpressed, contributing to cancer growth and progression. The drug T-DM1 targets these receptors, killing cancerous cells. Clinicians test tumor samples to determine HER2 status and decide whether T-DM1 is an appropriate treatment option.

6.2 Drug uptake

• Drug uptake is influenced by individual genomes: The genetic makeup of a person impacts how efficiently a drug is taken up by target cells and how quickly it’s excreted.
• Decreased permeability can lead to side effects: If a drug can’t easily enter target cells, it can accumulate in other areas, causing side effects.
• Fast excretion can reduce therapeutic effect: If a drug is excreted too quickly, it may not have enough time to exert its desired effect.
• Example: Statins and SLCO1B1 gene: Statins, used to lower cholesterol, require transport to the liver. Variations in the SLCO1B1 gene can reduce statin uptake, leading to potential muscle problems if higher doses are given.
• Genetic testing can help: Testing for variations in genes like SLCO1B1 can help clinicians make informed decisions about drug dosage and choice.

6.3 Drug breakdown

Extractive Summary:

• Genetic Influence on Drug Metabolism: An individual’s genes can significantly impact how quickly their body breaks down a drug.
• Drug Dosage Adjustment: If a drug is metabolized too fast, the dosage needs to be increased or a different drug may be required. If it’s metabolized too slowly, a lower dosage is needed.
• Example: Amitriptyline: The breakdown of this antidepressant is controlled by two genes (CYP2D6 and CYP2C19). Genetic testing can help determine the optimal dosage based on an individual’s gene activity.
• Cytochrome P450: A crucial protein family involved in drug metabolism. The CYP2D6 enzyme is responsible for breaking down many drugs.
• Drug Metabolizer Classifications: Based on CYP2D6 mutations, individuals are categorized as ultrafast, extensive, medium, or slow metabolizers.
• Pharmacogenomics and SNPs: Single nucleotide polymorphisms (SNPs) are a major focus in pharmacogenomics, as they can alter drug metabolism.
• Predicting Drug Responses: Pharmacogenomics aims to predict drug side effects through diagnostic testing. This allows for individualized therapy based on genetic predispositions.
• Stratified Medicine: This approach tailors therapy to a patient’s genetic makeup, exemplified by the use of mercaptopurine and thioguanine for acute lymphatic leukemia.
• Pharmacogenomics in Research: This field helps refine clinical trials by identifying participants who may not benefit from or experience adverse reactions to a drug, increasing the likelihood of a successful drug reaching the market.
• Developing New Drugs: Pharmacogenomics can assist in developing drugs for patients who haven’t responded to existing therapies.

7 Pharmacogenomics and targeted drug development

• Pharmacogenomics focuses on treating the cause of disease, not just symptoms.
• Mutations in genes can cause diseases, and different mutations in the same gene can have different effects.
• Drugs can be designed to target specific mutations.
• Ivacaftor, a cystic fibrosis drug, works by opening ion channels affected by a specific mutation in the CFTR gene.
• Factors beyond genetics, such as age, lifestyle, and other medications, can influence drug response.
• Genetic variation can influence metabolic pathways, but not always.
• Integrating pharmacogenomics and pharmaco-metabolomics allows for more personalized medicine.

7.1 Personalized medicine

• Personalized medicine (PM) tailors medical care based on an individual’s genetic makeup. It uses genotype information for disease prevention, diagnosis, treatment, and cures.
• The Human Genome Project’s data is fueling the advancement of PM.
• PM is a proactive approach to healthcare. It aims to manage health effectively and account for inherited predispositions.
• Technological advancements are accelerating the growth of PM. This includes faster and more accurate genome sequencing methods and extensive research databases linking genetic variants to diseases.

7.2 Personalized medicine drivers

• Personalized medicine is driven by the completion of human genome sequencing and the understanding of disease causes and patient heterogeneity. This knowledge allows for tailored treatments based on individual genetic makeup.
• The goal of personalized medicine is to improve the benefit-to-risk ratio of treatments by identifying more specific and safer medicines for individual patients.
• Understanding disease and patient heterogeneity will lead to the discovery of new disease-related targets and more sensitive diagnostic tools.
• Personalized medicine will offer a wider range of pharmacological options and enable earlier interventions.
• Diagnostic tools combined with pharmaceuticals will help healthcare providers choose the most effective and safe drug options for each patient.
• The full potential of personalized medicine for treating various diseases is still years away.

7.2.3 Search for biomarkers of drug response

• Heterogeneity in drug response: Factors like environment, disease complexity, drug interactions, individual health, and complications contribute to variations in how people respond to medications.
• Pharmacogenetics and Personalized Medicine: Understanding genetic factors influencing drug response is crucial for personalized medicine. The goal is to optimize efficacy and safety for each individual.
• Adverse Drug Events (ADEs) and Genetic Variance: Genetic differences can lead to adverse drug events, causing the withdrawal of drug candidates during development or removal of approved drugs after launch.
• Biomarkers for Drug Response: Biomarkers can help predict individual responses to specific drugs, aiding in personalized treatment. For example, biomarkers can indicate the risk of adverse effects, recommend appropriate doses, and identify potential drug targets.
• FDA-Approved Drugs and Biomarkers: The FDA has approved drugs for various diseases based on biomarkers. Table 5.1 lists examples of these drugs, the biomarkers associated with them, and their specific therapeutic areas.
• Future of Biomarker Research: Discovering new biomarkers is vital for identifying, targeting, and tailoring treatments for different infections and diseases.

7.3 Future aspects of pharmacogenomics in personalized medicine

• Challenges in Personalized Medicine: Managing disease severity is complex, and the impact of multiple genetic alterations is not fully understood.
• Importance of Biomarkers: Better disease biomarkers are needed for improved diagnosis and treatment.
• Role of Microbiome Research: Advancements in DNA sequencing allow for microbiome research, which could lead to personalized treatments.
• Pharmacogenomics and Personalized Treatment: Connecting genetic variations with their consequences is crucial. Pharmacogenomics focuses on clinical validation and application, but its clinical utility and cost-effectiveness need to be considered.
• Barriers to Wider Pharmacogenomics Use: Data and trials exist but are not widely implemented in medical services. Disparities exist between clinical performance and actual use of pharmacogenomics testing by healthcare professionals.
• Future Directions: Recommendations include using more biomarkers, developing privacy-protected genetic codes, ensuring equitable access to drugs, and promoting awareness of pharmacogenomics.

8 Computational biology methods for decision support in personalized medicine

• Challenges in Personalized Medicine: Integrating genetic information (genotypes) with patient medical history (phenotypes) is a significant challenge in personalized medicine.
• Role of Bioinformatics: Bioinformatics plays a vital role in integrating data from various levels (cells, genes, proteins, etc.) to support accurate diagnosis, personalized treatment recommendations, and efficient healthcare management.
• Data Integration for Personalized Medicine: Combining laboratory and clinical data through translational bioinformatics methods can improve decision-making in healthcare.
• Large Databases and Data Mining: Creating comprehensive databases and utilizing data mining techniques, like RNA-SEQ Atlas, allows for discovering new insights and improving skill proficiency.
• Data Standardization: Standardization efforts, like SNOMED CT, ICD, and DICOM, are crucial for resolving interoperability issues across different medical and laboratory settings.
• Knowledge Discovery (KD): KD is an iterative process using data integration and data mining techniques to find effective pharmacological targets and implement personalized treatments.
• Data Mining Techniques: Methods like neural networks, Bayesian networks, text data mining, and agent-based modeling are used in data mining to analyze complex systems and identify patterns.
• Applications of Computational Biology: Examples like gene expression analysis in lung tissue, breast cancer detection using dynamic thermal analysis (DTA) and artificial neural networks (ANN), and modeling mammary ductal epithelium dynamics illustrate the applications of computational biology in healthcare.
• Semantic Web Technologies: Semantic web technologies can help organize and display pharmacogenomics knowledge, supporting drug development and medical decision-making.

8.1 Pharmacogenomics information

• Pharmacogenomics databases are crucial for personalized medicine and pharmacogenetics.
• The aim of pharmacogenomics is to identify biomarkers predicting drug toxicity and body response.
• This personalization improves patient treatment effectiveness.
• The text lists several pharmacogenomics web resources:
  • PharmGKB
  • CPIC
  • DrugBank
  • SCAN
  • PACdb
  • Human Cytochrome P450 Allele Nomenclature database (transitioned to PharmVar)
  • Cytochrome P450 Drug Interaction Table
  • FDA’s pharmacogenetic website

8.1.3 CPIC

• CPIC’s Formation and Purpose: CPIC was established in 2009, collaborating with PRN and PharmGKB. Its aim is to provide specific gene/drug clinical practice recommendations to integrate pharmacogenomics into clinical practice.
• CPIC’s Methodology: CPIC gathers scientific data from various levels, including biological findings and clinical trials, and incorporates it into their standards.
• CPIC’s Focus: The recommendations focus on how genetic testing can enhance medication therapy, not on the reasons for testing.
• CPIC’s Current Scope: CPIC currently covers 174 drug/gene combinations, encompassing 63 genes and 132 therapeutics.
• CPIC’s Expert Review and Accessibility: Each recommendation is reviewed by experts, updated regularly, and accessible to the public on the CPIC website.